Emerging Antiviral Resistant Strains of Influenza A and the Potential Therapeutic Targets Within the Viral Ribonucleoprotein (vRNP) Complex

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2014 Sep 18

PMID 25228366

Citations 9

Authors

Alicia M Davis

Bryan J Chabolla

Laura L Newcomb

Affiliations

Soon will be listed here.

Abstract

Emerging antiviral resistant strains of influenza A virus are greatly limiting the therapies available to stop aggressive infections. Genome changes that confer resistance to the two classes of approved antivirals have been identified in circulating influenza A viruses. It is only a matter of time before the currently approved influenza A antivirals are rendered ineffective, emphasizing the need for additional influenza antiviral therapies. This review highlights the current state of antiviral resistance in circulating and highly pathogenic influenza A viruses and explores potential antiviral targets within the proteins of the influenza A virus ribonucleoprotein (vRNP) complex, drawing attention to the viral protein activities and interactions that play an indispensable role in the influenza life cycle. Investigation of small molecule inhibition, accelerated by the use of crystal structures of vRNP proteins, has provided important information about viral protein domains and interactions, and has revealed many promising antiviral drug candidates discussed in this review.

Citing Articles

Evaluation of the Antiviral Activity of Tabamide A and Its Structural Derivatives against Influenza Virus.

Shin S, Lee J, Kim J, Im W, Damodar K, Woo H Int J Mol Sci. 2023; 24(24).

PMID: 38139128 PMC: 10744247. DOI: 10.3390/ijms242417296.

Conserved Targets to Prevent Emerging Coronaviruses.

Gonzalez Lomeli F, Elmaraghy N, Castro A, Osuna Guerrero C, Newcomb L Viruses. 2022; 14(3).

PMID: 35336969 PMC: 8949862. DOI: 10.3390/v14030563.

Development and Effects of Influenza Antiviral Drugs.

Yin H, Jiang N, Shi W, Chi X, Liu S, Chen J Molecules. 2021; 26(4).

PMID: 33557246 PMC: 7913928. DOI: 10.3390/molecules26040810.

Influenza A Virus Utilizes Low-Affinity, High-Avidity Interactions with the Nuclear Import Machinery To Ensure Infection and Immune Evasion.

Tome-Amat J, Ramos I, Amanor F, Fernandez-Sesma A, Ashour J J Virol. 2018; 93(1).

PMID: 30305352 PMC: 6288324. DOI: 10.1128/JVI.01046-18.

Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.

Hu Y, Sneyd H, Dekant R, Wang J Curr Top Med Chem. 2017; 17(20):2271-2285.

PMID: 28240183 PMC: 5967877. DOI: 10.2174/1568026617666170224122508.

References

Ng A, Chan W, Choi S, Lam M, Lau K, Chan P . Influenza polymerase activity correlates with the strength of interaction between nucleoprotein and PB2 through the host-specific residue K/E627. PLoS One. 2012; 7(5):e36415. PMC: 3343083. DOI: 10.1371/journal.pone.0036415. View

Fukuoka M, Minakuchi M, Kawaguchi A, Nagata K, Kamatari Y, Kuwata K . Structure-based discovery of anti-influenza virus A compounds among medicines. Biochim Biophys Acta. 2011; 1820(2):90-5. DOI: 10.1016/j.bbagen.2011.11.003. View

Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K . Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004; 364(9436):759-65. DOI: 10.1016/S0140-6736(04)16934-1. View

Perez D, Donis R . Functional analysis of PA binding by influenza a virus PB1: effects on polymerase activity and viral infectivity. J Virol. 2001; 75(17):8127-36. PMC: 115057. DOI: 10.1128/jvi.75.17.8127-8136.2001. View

Jing X, Ma C, Ohigashi Y, Oliveira F, Jardetzky T, Pinto L . Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci U S A. 2008; 105(31):10967-72. PMC: 2492755. DOI: 10.1073/pnas.0804958105. View

Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W . Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013; 368(20):1888-97. DOI: 10.1056/NEJMoa1304459. View

Meindl P, Bodo G, Palese P, Schulman J, Tuppy H . Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology. 1974; 58(2):457-63. DOI: 10.1016/0042-6822(74)90080-4. View

Marklund J, Ye Q, Dong J, Tao Y, Krug R . Sequence in the influenza A virus nucleoprotein required for viral polymerase binding and RNA synthesis. J Virol. 2012; 86(13):7292-7. PMC: 3416340. DOI: 10.1128/JVI.00014-12. View

Cros J, Garcia-Sastre A, Palese P . An unconventional NLS is critical for the nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein. Traffic. 2005; 6(3):205-13. DOI: 10.1111/j.1600-0854.2005.00263.x. View

10.

Biswas S, Boutz P, Nayak D . Influenza virus nucleoprotein interacts with influenza virus polymerase proteins. J Virol. 1998; 72(7):5493-501. PMC: 110190. DOI: 10.1128/JVI.72.7.5493-5501.1998. View

11.

Perez D, Donis R . A 48-amino-acid region of influenza A virus PB1 protein is sufficient for complex formation with PA. J Virol. 1995; 69(11):6932-9. PMC: 189611. DOI: 10.1128/JVI.69.11.6932-6939.1995. View

12.

Kawaguchi A, Momose F, Nagata K . Replication-coupled and host factor-mediated encapsidation of the influenza virus genome by viral nucleoprotein. J Virol. 2011; 85(13):6197-204. PMC: 3126543. DOI: 10.1128/JVI.00277-11. View

13.

Guilligay D, Tarendeau F, Resa-Infante P, Coloma R, Crepin T, Sehr P . The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol. 2008; 15(5):500-6. DOI: 10.1038/nsmb.1421. View

14.

Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J . Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet. 2013; 381(9881):1916-25. PMC: 7134567. DOI: 10.1016/S0140-6736(13)60903-4. View

15.

Sugiyama K, Obayashi E, Kawaguchi A, Suzuki Y, Tame J, Nagata K . Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. EMBO J. 2009; 28(12):1803-11. PMC: 2699363. DOI: 10.1038/emboj.2009.138. View

16.

Neumann G, Noda T, Kawaoka Y . Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009; 459(7249):931-9. PMC: 2873852. DOI: 10.1038/nature08157. View

17.

Cianci C, Gerritz S, Deminie C, Krystal M . Influenza nucleoprotein: promising target for antiviral chemotherapy. Antivir Chem Chemother. 2012; 23(3):77-91. DOI: 10.3851/IMP2235. View

18.

Deng T, Vreede F, Brownlee G . Different de novo initiation strategies are used by influenza virus RNA polymerase on its cRNA and viral RNA promoters during viral RNA replication. J Virol. 2006; 80(5):2337-48. PMC: 1395412. DOI: 10.1128/JVI.80.5.2337-2348.2006. View

19.

Shen Y, Chen Y, Chu S, Lin M, Hsu H, Wu P . E339...R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors. Proc Natl Acad Sci U S A. 2011; 108(40):16515-20. PMC: 3189076. DOI: 10.1073/pnas.1113107108. View

20.

Honda A, Ueda K, Nagata K, Ishihama A . RNA polymerase of influenza virus: role of NP in RNA chain elongation. J Biochem. 1988; 104(6):1021-6. DOI: 10.1093/oxfordjournals.jbchem.a122569. View